Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for Hemolysis in Impella Patients
NCT04391231Phase 4Withdrawn
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hemolysis comparing Pentoxifylline Arm with Placebo Arm (2 arms). Primary endpoint: Reduction in REBC hemolysis at 30 days. Planned start Jun 2020; status: withdrawn.
02
Drugs
pentoxifylline
03
Conditions
hemolysis
Beyond the preview
Go deeper on NCT04391231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391231.